BeOne Medicines Ltd.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
BeOne Medicines (formerly BeiGene) develops and markets cancer therapies, including its own discovered drugs such as the BTK inhibitor Brukinsa and the PD-1 inhibitor tislelizumab, alongside a pipeline of other oncology treatments. The company operates global R&D and manufacturing operations across the U.S., China, Switzerland, and other markets.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Wang XiaodongDirector | Sell | $3.63M | 10,361at $350.47 | Oct 13, 2026 |
| Wang XiaodongDirector | Sell | $2.31M | 6,558at $352.57 | Oct 13, 2026 |
| Wang XiaodongDirector | Sell | $445K | 1,260at $353.24 | Oct 13, 2026 |
| Wang XiaodongDirector | Sell | $2.51M | 7,167at $349.56 | Oct 13, 2026 |
| Wang XiaodongDirector | Sell | $2.00M | 5,681at $351.40 | Oct 13, 2026 |
| Lee Chan HenrySVP, General Counsel | Sell | $960K | 2,666at $360.00 | Aug 11, 2026 |
| Rosenberg AaronChief Financial Officer | Sell | $362K | 1,157at $312.71 | Aug 3, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable ONC activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.